Shafiq Samiyah, Hamashima Kiyofumi, Guest Laura A, Al-Anbaki Ali H, Amaral Fabio M R, Wiseman Daniel H, Kouskoff Valerie, Lacaud Georges, Loh Yuin-Han, Batta Kiran
Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK; Cell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Cell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Stem Cell Reports. 2025 May 13;20(5):102473. doi: 10.1016/j.stemcr.2025.102473. Epub 2025 Apr 3.
Direct reprogramming of somatic cells offers a potentially safer therapeutic approach to generate patient-specific hematopoietic cells. However, this strategy is limited by stochasticity of reprogramming. Investigating the gene regulatory networks involved during reprogramming would help generate functional cells in adequate numbers. To address this, we developed an inducible system to reprogram fibroblasts to hematopoietic progenitor cells by ectopically expressing the two transcription factors SCL and LMO2. Transcriptome and epigenome analysis at different stages of reprogramming revealed uniform silencing of fibroblast genes and upregulation of the hemogenic endothelial program. Integrated analysis suggested that the transcription factors FLI1, GATA1/2, and KLF14 are direct targets of SCL/LMO2, which subsequently induce the hematopoietic program. Single-cell RNA sequencing revealed conflicting and competing fate decisions at intermediate stages of reprogramming. Inhibiting signaling pathways associated with competing neuronal fate enhanced reprogramming efficiency. In conclusion, this study identifies early/intermediate reprogramming events and associated pathways that could be targeted to improve reprogramming efficiency.
体细胞的直接重编程为生成患者特异性造血细胞提供了一种潜在更安全的治疗方法。然而,这种策略受到重编程随机性的限制。研究重编程过程中涉及的基因调控网络将有助于生成足够数量的功能细胞。为了解决这个问题,我们开发了一种诱导系统,通过异位表达两种转录因子SCL和LMO2,将成纤维细胞重编程为造血祖细胞。重编程不同阶段的转录组和表观基因组分析揭示了成纤维细胞基因的均匀沉默和造血内皮程序的上调。综合分析表明,转录因子FLI1、GATA1/2和KLF14是SCL/LMO2的直接靶点,随后诱导造血程序。单细胞RNA测序揭示了重编程中间阶段相互冲突和竞争的命运决定。抑制与竞争性神经元命运相关的信号通路可提高重编程效率。总之,本研究确定了早期/中间重编程事件以及相关途径,这些途径可作为靶点来提高重编程效率。